Timolol maleate 0.5% or 0.1% gel-forming solution for infantile hemangiomas: a retrospective, multicenter, cohort study.
about
Beta-blockers for prevention and treatment of retinopathy of prematurity in preterm infantsBeta-blockers as therapy for infantile hemangiomasTopical Application of 0.5% Timolol Maleate Hydrogel for the Treatment of Superficial Infantile Hemangioma.Beta blockers: an innovation in the treatment of infantile hemangiomas.Fractional carbon dioxide laser-assisted drug delivery of topical timolol solution for the treatment of deep infantile hemangioma: a pilot study.Treatment of port wine stains with pulsed dye laser and topical timolol: a multicenter randomized controlled trial.Topical timolol solution versus laser in treatment of infantile hemangioma: a comparative study.Pulsed dye laser and topical timolol gel versus pulse dye laser in treatment of infantile hemangioma: A double-blind randomized controlled trial.Efficacy of low-dose (90)Sr-(90)Y therapy combined with topical application of 0.5% timolol maleate solution for the treatment of superficial infantile hemangiomas.Nd:YAG and pulsed dye laser therapy in infantile haemangiomas: a retrospective analysis of 271 treated haemangiomas in 149 children.Prospective, open-label, rater-blinded and self-controlled pilot study of the treatment of proliferating superficial infantile hemangiomas with 0.5% topical timolol cream versus 595-nm pulsed dye laser.A prospective study to assess the efficacy and safety of oral propranolol as first-line treatment for infantile superficial hemangioma.β-blockers: a novel class of antitumor agents.Efficacious Healing of Ulcerated Infantile Hemangiomas Using Topical Timolol.Efficacy of topical brimonidine-timolol for haemangioma of infancy and perils of off-label prescribingInfantile hemangiomas: A review.Increasing incidence of infantile hemangiomas (IH) over the past 35 years: Correlation with decreasing gestational age at birth and birth weightResolution of conjunctival sessile hemangioma with topical timolol.Infantile hemangiomas: an update.Propranolol and infantile hemangiomas four years later: a systematic review.Early surgical excision of giant congenital hemangiomas of the scalp in newborns: clinical indications and reconstructive aspects.Haemangioma: clinical course, complications and management.Beta-blockers versus corticosteroids in the treatment of infantile hemangioma: an evidence-based systematic review.The use of propranolol in the treatment of infantile haemangiomas: an update on potential mechanisms of action.Incidence and treatment of infantile haemangioma in preterm infants.Treatment of rapidly proliferating haemangiomas in newborns with propranolol and review of the literature.Novel treatment for infantile hemangiomasTreatment of infantile hemangiomas: therapeutic options in regard to side effects and adverse events - a review of the literature.Assessment of the effectiveness of topical propranolol 4% gel for infantile hemangiomas.Effect of propranolol on the treatment of infantile hemangiomas: a single tertiary center 3-year experience.Adverse Events in Young and Preterm Infants Receiving Topical Timolol for Infantile Hemangioma.Outpatient use of oral propranolol and topical timolol for infantile hemangiomas: survey results and comparison with propranolol consensus statement guidelines.Evaluation of skin permeation of β-blockers for topical drug delivery.Safety and efficacy of topical timolol treatment of infantile haemangioma: A prospective trial.Imiquimod 5% cream versus timolol 0.5% ophthalmic solution for treating superficial proliferating infantile haemangiomas: a retrospective study.Topical timolol maleate for treatment of infantile haemangiomas: preliminary results of a prospective study.Topical timolol 0.5% gel-forming solution for small deep facial infantile hemangiomas.Topical timolol for infantile hemangiomas: putting a note of caution in "cautiously optimistic".Treatment of pediatric pyogenic granulomas using β-adrenergic receptor antagonists.Review of the 92nd Annual Meeting of the British Association of Dermatologists, 3-5 July 2012, Birmingham, U.K.
P2860
Q24187442-DE83921F-18B3-400A-9136-C29E85189F94Q33832594-5EEC755B-C8AB-418A-A1FB-8A21D4B4F990Q33835368-F9FA74AB-609B-4497-826C-B459E99140A0Q33931306-B72FF517-8579-4484-951A-F9AC4FFA9A3CQ35112393-6C61272E-0C11-4716-88A7-2642A96B1683Q35123506-07ED5BBE-4E7B-40A9-9CCA-F2A25CDB2FE5Q35571889-73499A0F-B77A-47B8-84DE-85A40DB76634Q35936708-4E45B448-9576-46C3-9D82-E409693E8122Q35942904-D0362535-FA90-4F8F-8D74-A287EDCD26B1Q36211734-E2EE842D-92D5-457C-B21B-DCF1AD34F6DEQ36278223-591D806A-25AE-4707-A406-BE994F6D5351Q36442155-4069B011-0C3E-4EB9-9BEF-F3623C64E3D2Q36443830-ED4A96FB-F7A9-484D-A297-59829422DA60Q36653309-911D2FFC-D61D-4D4D-8167-482F72A256B1Q36819102-4BABB675-8269-4D86-8B59-B9D5DCA1086DQ37059898-00A6580C-10CB-4318-9D3F-625E3E2DC8B6Q37197527-84021AF7-DAD6-4CFB-AE22-4F45084BCA2DQ37492417-3B340D31-A5CD-4F10-8231-5DF384560A87Q38075847-E0A2D481-1889-4017-97A5-D4F34BECE1D4Q38081161-F433EDE0-596A-4902-A815-C202E8728BCBQ38098648-3F6BD8D7-10D2-40CF-A9F1-3162C18E669AQ38108844-094D77E5-75E7-4EF5-A74C-4076C2528489Q38127617-9CFE07AA-1B5B-4416-B9A8-4DC4BBC09C89Q38246692-0D00698E-273D-4C13-A272-929F9871F43CQ38263431-416B942A-A73A-4992-A9AF-D2CE84D78FC9Q38266789-BCFEA3E9-403F-4EF8-A461-B11CD4800AF0Q38286973-8DCDC7C3-911B-43EA-A41B-CCDDE2E7FE8FQ38662656-B22E5638-6DCB-4211-AF42-0D9A6C8BB8B9Q39027849-733E0CDC-A189-4F64-8C66-952CBFCD6B40Q40082831-2F3A587A-9E08-4461-A4BA-0615C8A33D10Q40725867-D06606A5-9DA0-43A8-949A-BA88F803570AQ41628385-19230265-7698-415A-87BB-C90D8C1C78C8Q42910405-36F19F4C-193D-4A31-B0F2-E36C5C15C21DQ43973289-1E382091-3310-4D3F-A0B5-DA25EFAAEDBFQ44360789-086F200E-744D-4B8D-BA1E-EF9828186EEAQ44478617-7A894422-FA70-4B5C-9040-965CFF01ED57Q44482425-965445EB-B670-4B8F-97F1-CC8133512888Q45984471-27D94258-C9E9-4C79-9B86-1F787708F3E9Q45996317-506CAC53-BDFD-49C9-9DC1-F3E3F21A5365Q46964953-C2EFDDA9-1D2B-4A67-82FB-546ED2F4348D
P2860
Timolol maleate 0.5% or 0.1% gel-forming solution for infantile hemangiomas: a retrospective, multicenter, cohort study.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Timolol maleate 0.5% or 0.1% g ...... ve, multicenter, cohort study.
@en
Timolol maleate 0.5% or 0.1% g ...... ve, multicenter, cohort study.
@nl
type
label
Timolol maleate 0.5% or 0.1% g ...... ve, multicenter, cohort study.
@en
Timolol maleate 0.5% or 0.1% g ...... ve, multicenter, cohort study.
@nl
prefLabel
Timolol maleate 0.5% or 0.1% g ...... ve, multicenter, cohort study.
@en
Timolol maleate 0.5% or 0.1% g ...... ve, multicenter, cohort study.
@nl
P2093
P2860
P1476
Timolol maleate 0.5% or 0.1% g ...... ve, multicenter, cohort study.
@en
P2093
Ajith Chakkittakandiyil
Elaine Siegfried
Elena Pope
Irene Lara-Corrales
James Bergmann
Joseph Lam
Philip Bekhor
Rod Phillips
Solmaz Poorsattar
P2860
P356
10.1111/J.1525-1470.2011.01664.X
P577
2011-12-09T00:00:00Z